Last reviewed 2026-05-22 · How we verify

Mesulphen (MESULFEN)

Phase 2 active Small molecule ✓ Verified May 2026

Mesulphen (generic name: MESULFEN) is a mesulfen drug. It is currently in Phase 2 development.

Mesulphen works by interacting with specific biological molecules to modulate their activity.

Mesulphen is a small molecule with the synonyms MESULFEN, MESULFENE, MESULFENO, MITIGAL, and NEOSULFINE.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	MESULFEN
Drug class	mesulfen
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells are like a orchestra, and each cell has its own set of instructions. Mesulphen is like a conductor that helps the cells follow the right instructions, but we don't know exactly how it does that yet.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Mesulphen CI brief — competitive landscape report
Mesulphen updates RSS · CI watch RSS

Frequently asked questions about Mesulphen

What is Mesulphen?

Mesulphen (MESULFEN) is a mesulfen drug.

How does Mesulphen work?

Mesulphen works by interacting with specific biological molecules to modulate their activity.

What is the generic name of Mesulphen?

MESULFEN is the generic (nonproprietary) name of Mesulphen.

What drug class is Mesulphen in?

Mesulphen belongs to the mesulfen class. See all mesulfen drugs at /class/mesulfen.

What development phase is Mesulphen in?

Mesulphen is in Phase 2.

Drug class: All mesulfen drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing